Broad-spectrum mono- and combinational drug therapies for global viral pandemic preparedness
Aleksandr Ianevski, Rouan Yao, Ronja M. Simonsen, Vegard Myhre, Erlend Ravlo, Gerda D. Kaynova, Eva Žusinaite, Judith M. White, Stephen J. Polyak, Valentyn Oksenych, Marc Peter Windisch, Qiuwei Pan, Eglė Lastauskienė, Astra Vitkauskienė, Algimantas Matukevičius, Tanel Tenson, Magnar Bjørås, Denis E. Kainov · bioRxiv (Cold Spring Harbor Laboratory) · 2022
Abstract Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by analyzing conserved druggable virus-host interactions, mechanisms of action and immunomodulatory properties of broad-spectrum antivirals (BSAs), routes of BSA delivery, and BSA interactions with other antivirals. Based on the analysis we developed scoring systems, which allowed us to predict novel BSAs and BSA-containing drug combinations (BCCs). Thus, we have developed a new strategy to broaden the spectrum of BSA indications and predict novel mono-and combinational therapies that can help better prepare for imminent future viral outbreaks. Abstract Figure